Increased adhesion molecule levels in systemic lupus erythematosus: relationships with severity of illness,autoimmunity,metabolic syndrome and cortisol levels
Restricted accessResearch articleFirst published online March, 2018
Increased adhesion molecule levels in systemic lupus erythematosus: relationships with severity of illness,autoimmunity,metabolic syndrome and cortisol levels
This study was performed to assess adhesion molecules in systemic lupus erythematosus (SLE).
Methods
This case-control study examined 126 SLE patients and 48 healthy individuals. Blood levels of six adhesion molecules, cortisol, nuclear autoantibody (ANA) and anti-double stranded DNA (anti-dsDNA) titers were measured, while disease activity was assessed using the SLE Disease Activity Index (SLEDAI) score.
Results
Platelet endothelial cell adhesion molecule 1 (PECAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-selectin, P-selectin, and plasminogen activator inhibitor type-1 (PAI-1) were significantly higher in SLE patients than in controls. Binary logistic regression analysis showed that PECAM-1 and PAI-1 predicted SLE with a sensitivity of 86.5% and a specificity of 81.3%. ANA titers were significantly and positively associated with PECAM-1, VCAM-1, E-selectin, and PAI-1, whereas there were no associations between anti-dsDNA titers and adhesion molecules. Cortisol was negatively associated with PCAM-1 and ICAM-1. There were significant associations between metabolic syndrome (MetS) and E-selectin and PAI-1. 14.8% of the variance in the SLEDAI score was explained by the regression on PECAM-1 and MetS.
Conclusions
Our data show that adhesion molecules, especially PECAM-1, are significantly associated with SLE and disease activity, suggesting that they play a role in SLE pathophysiology. While MetS, ANA titers and cortisol levels modulate adhesion molecule levels, these associations do not explain the increased levels of adhesion molecules in SLE. Increased levels of adhesion molecules are new drug targets in SLE.
SpringerTA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell1994; 76: 301–314.
2.
SkeochSHaqueSPembertonPBruceI. Cell adhesion molecules as potential biomarkers of nephritis, damage and accelerated atherosclerosis in patients with SLE. Lupus2014; 23: 819–824.
3.
LewisMVyseSShieldsAet al.Improved monitoring of clinical response in systemic lupus erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1. Arthritis Res Ther2016; 18: 1–11.
4.
BertsiasGCerveraRBoumpasDT. Systemic lupus erythematosus: Pathogenesis and clinical features. EULAR textbook on rheumatic diseases, London: BMJ, 2012, pp. 476–505.
5.
HejaziEZWerthVP. Cutaneous lupus erythematosus: An update on pathogenesis, diagnosis and treatment. Am J Clin Dermatol2016; 17: 135–146.
6.
MikdashiJA. Altered functional neuronal activity in neuropsychiatric lupus: A systematic review of the fMRI investigations. Semin Arthritis Rheum2016; 45: 455–462.
7.
LalwaniPSouzaGKBBLimaDSNPassosLFBoechatALLimaES. Serum thiols as a biomarker of disease activity in lupus nephritis. PLoS One2015; 10: 1–12.
HirataTUsuiTKobayashiSMimoriT. A novel splice variant of human L-selectin encodes a soluble molecule that is elevated in serum of patients with rheumatic diseases. Biochem Biophys Res Commun2015; 462: 371–377.
BartoloniEShoenfeldYGerliR. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: Two faces of the same coin. Arthritis Care Res2011; 63: 178–183.
12.
GoesMCBossemaERHartkampAet al.Cortisol during the day in patients with systemic lupus erythematosus or primary Sjögren’s syndrome. J Rheumatol2011; 38: 285–288.
13.
CutoloMSulliAVillaggioBSerioloBAccardoS. Relations between steroid hormones and cytokines in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis1998; 57: 573–577.
14.
CronsteinBNKimmelSCLevinRIMartiniukFWeissmannG. A mechanism for the antiinflammatory effects of corticosteroids: The glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. PNAS1992; 89: 9991–9995.
15.
ReavenGM. Banting lecture 1988. Role of insulin resistance in human disease. 1988. Nutrition1997; 13: 65–65. discussion 64, 66.
16.
ScharamMTStehouwerCDA. Endothelial dysfunction, cellular adhesion molecules and the metabolic syndrome. Horm Metab Res2005; 37(Suppl. 1): 49–55.
17.
LozovoyMABSimãoANCHohmannMSNet al.Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus2011; 20: 1356–1364.
18.
McMahonMHahnBHSkaggsBJ. Systemic lupus erythematosus and cardiovascular disease: Prediction and potential for therapeutic intervention. Expert Rev Clin Immunol2011; 7: 227–241.
19.
KarrarASequeiraWBlockJA. Coronary artery disease in systemic lupus erythematosus: A review of the literature. Semin Arthritis Rheum2001; 30: 436–443.
20.
MokCCPoonWLLaiJPSet al.Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol2010; 39: 42–49.
21.
RyanMJ. The pathophysiology of hypertension in systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol2009; 296: R1258–R1267.
22.
El-MagadmiMBodillHAhmadYet al.Systemic lupus erythematosus: An independent risk factor for endothelial dysfunction in women. Circulation2004; 110: 399–404.
23.
BelmontHMBuyonJGiornoRAbramsonS. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum1994; 37: 376–383.
24.
RhoYHChungCPOeserAet al.Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol2008; 35: 1789–1794.
25.
HochbergMC. Updating the American College of Rheumatology. Arthritis Rheum1997; 40: 1725–1734.
26.
GrundySMCleemanJIDanielsSRet al.Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation2005; 112: 2735–2752.
27.
JamesPAOparilSCarterBLet al.2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA2014; 311: 507–520.
28.
WuTXieCWangHWet al.Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol2007; 179: 7166–7175.
29.
EgererKFeistERohrUPrussABurmesterGRDörnerT. Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus2000; 9: 614–621.
30.
SomersECMarderWKaplanMJBrookRDMcCuneWJ. Plasminogen activator inhibitor-1 is associated with impaired endothelial function in women with systemic lupus erythematosus. Ann NY Acad Sci2005; 1051: 271–280.
31.
AdamskaAKarczewska-KupczewskaMNikołajukAet al.Relationships of serum soluble E-selectin concentration with insulin sensitivity and metabolic flexibility in lean and obese women. Endocrine2014; 45: 422–429.
32.
MatsumotoKSeraYAbeYet al.High serum concentrations of soluble E-selectin correlate with obesity but not fat distribution in patients with type 2 diabetes mellitus. Metabolism2002; 51: 932–934.
33.
TrøseidMLappegårdKTMollnesTEArnesenHSeljeflotI. Changes in serum levels of E-selectin correlate to improved glycaemic control and reduced obesity in subjects with the metabolic syndrome. Scand J Clin Lab Invest2005; 65: 283–290.
34.
BarnardSAPietersMDe LangeZ. The contribution of different adipose tissue depots to plasma plasminogen activator inhibitor-1 (PAI-1) levels. Blood Rev2016; 30: 421–429.
35.
AlessiMCJuhan-VagueI. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost2008; 99: 995–1000.
36.
GutiérrezMAGarciaMERodriguezJARiveroSJacobelliS. Hypothalamic-pituitary-adrenal axis function and prolactin secretion in systemic lupus erythematosus. Lupus1998; 7: 404–408.
37.
SealsDRJablonskiKLDonatoAJ. Aging and vascular endothelial function in humans. Clin Sci2011; 120: 357–375.
38.
MullerWA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol2003; 24: 326–333.
39.
VestweberD. Regulation of endothelial cell contacts during leukocytes extravasation. Curr Opin Cell Biol2002; 14: 587–593.
40.
PrivratskyJRNewmanDKNewmanPJ. PECAM-1: Conflicts of Interest in Inflammation. Life Sci2010; 87: 69–82.
41.
AhearnJMLiuCKaoAHManziS. Biomarkers for systemic lupus erythematosus. Transl Res2012; 159: 326–342.
42.
SpronkPEBootsmaHHuitemaMGLimburgPCKallenbergCG. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol1994; 97: 439–444.
43.
DichiISimãoANC. Metabolic syndrome: new targets for an old problem. Expert Opin Ther Targets2012; 16: 147–150.
44.
Walkiewicz-PielaszekKSwachaMBułło-PionteckaBRutkowskiBOlesińskaM. Mycophenolate mofetil – 20 years of experience in treatment of rheumatic diseases. Postep Hig Med Dosw2015; 69: 176–187.
45.
WeigelGBertalanffyPWolnerE. Depletion of intracellular GTP results in nuclear factor-kappa B activation and intercellular adhesion molecule-1 expression in human endothelial cells. Mol Pharmacol2002; 62: 453–462.
46.
RaabMDaxeckerHKarimiAet al.In vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cells. Clin Chim Acta2001; 310: 89–98.
HauserIAJohnsonDRThevenodFGoppelt-StrubeM. Effect of mycophenolic acid on TNF alpha-induced expression of cell adhesion molecules in human venous endothelial cells in vitro. Br J Pharmacol1997; 122: 1315–1322.
